Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions

[1] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J]. BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921): : 81 - 100

[2] ACC/AHA 2007 guide lines for the management of patients with unstable Angina/Non-ST-Elevation myocardial infraction - Executive summary [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (07) : 652 - 726

[3] Tackling the diabetic platelet: is high clopidogrel dosing the answer? [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (12) : 2563 - 2565

[4] Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease [J]. DIABETES, 2006, 55 (03) : 780 - 784

[5] Influence of Aspirin resistance on platelet function profiles in patients on long-term Aspirin and Clopidogrel after percutaneous coronary intervention [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (01) : 38 - 43

[6] Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment [J]. DIABETES, 2005, 54 (08) : 2430 - 2435

[7] High clopidogrel loading dose during coronary stenting:: effects on drug response and interindividual variability [J]. EUROPEAN HEART JOURNAL, 2004, 25 (21) : 1903 - 1910

[8] ANGIOLILLO DJ, 2008, THROMB RES 1118

[9] Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mechanism of action and clinical development [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (16) : 2893 - 2900

[10] Angiolillo Dominick J, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P124, DOI 10.1097/MED.0b013e32807f2ad9

[1] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J]. BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921): : 81 - 100

[2] ACC/AHA 2007 guide lines for the management of patients with unstable Angina/Non-ST-Elevation myocardial infraction - Executive summary [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (07) : 652 - 726

[3] Tackling the diabetic platelet: is high clopidogrel dosing the answer? [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (12) : 2563 - 2565

[4] Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease [J]. DIABETES, 2006, 55 (03) : 780 - 784

[5] Influence of Aspirin resistance on platelet function profiles in patients on long-term Aspirin and Clopidogrel after percutaneous coronary intervention [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (01) : 38 - 43

[6] Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment [J]. DIABETES, 2005, 54 (08) : 2430 - 2435

[7] High clopidogrel loading dose during coronary stenting:: effects on drug response and interindividual variability [J]. EUROPEAN HEART JOURNAL, 2004, 25 (21) : 1903 - 1910

[8] ANGIOLILLO DJ, 2008, THROMB RES 1118

[9] Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mechanism of action and clinical development [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (16) : 2893 - 2900

[10] Angiolillo Dominick J, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P124, DOI 10.1097/MED.0b013e32807f2ad9